Literature DB >> 27236500

Aeroallergen-induced IL-33 predisposes to respiratory virus-induced asthma by dampening antiviral immunity.

Jason P Lynch1, Rhiannon B Werder1, Jennifer Simpson1, Zhixuan Loh1, Vivian Zhang1, Ashraful Haque2, Kirsten Spann3, Peter D Sly4, Stuart B Mazzone1, John W Upham5, Simon Phipps6.   

Abstract

BACKGROUND: Frequent viral lower respiratory infections in early life are an independent risk factor for asthma onset. This risk and the development of persistent asthma are significantly greater in children who later become sensitized.
OBJECTIVE: We sought to elucidate the pathogenic processes that underlie the synergistic interplay between allergen exposures and viral infections.
METHODS: Mice were inoculated with a murine-specific Pneumovirus species (pneumonia virus of mice [PVM]) and exposed to low-dose cockroach extract (CRE) in early and later life, and airway inflammation, remodeling, and hyperreactivity assessed. Mice were treated with anti-IL-33 or apyrase to neutralize or block IL-33 release.
RESULTS: PVM infection or CRE exposure alone did not induce disease, whereas PVM/CRE coexposure acted synergistically to induce the hallmark features of asthma. CRE exposure during viral infection in early life induced a biphasic IL-33 response and impaired IFN-α and IFN-λ production, which in turn increased epithelial viral burden, airway smooth muscle growth, and type 2 inflammation. These features were ameliorated when CRE-induced IL-33 release was blocked or neutralized, whereas substitution of CRE with exogenous IL-33 recapitulated the phenotype observed in PVM/CRE-coexposed mice. Mechanistically, IL-33 downregulated viperin and interferon regulatory factor 7 gene expression and rapidly degraded IL-1 receptor-associated kinase 1 expression in plasmacytoid dendritic cells both in vivo and in vitro, leading to Toll-like receptor 7 hyporesponsiveness and impaired IFN-α production.
CONCLUSION: We identified a hitherto unrecognized function of IL-33 as a potent suppressor of innate antiviral immunity and demonstrate that IL-33 contributes significantly to the synergistic interplay between respiratory virus and allergen exposures in the onset and progression of asthma.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-33; Pneumonia virus of mice; antiviral; interferon; plasmacytoid dendritic cell; respiratory syncytial virus; type 2 innate lymphoid cell

Mesh:

Substances:

Year:  2016        PMID: 27236500     DOI: 10.1016/j.jaci.2016.02.039

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  37 in total

1.  Human TH1 and TH2 cells targeting rhinovirus and allergen coordinately promote allergic asthma.

Authors:  Lyndsey M Muehling; Peter W Heymann; Paul W Wright; Jacob D Eccles; Rachana Agrawal; Holliday T Carper; Deborah D Murphy; Lisa J Workman; Carolyn R Word; Sarah J Ratcliffe; Brian J Capaldo; Thomas A E Platts-Mills; Ronald B Turner; William W Kwok; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2020-04-19       Impact factor: 10.793

2.  A novel function of IL-33: suppression of innate antiviral immunity.

Authors:  Akio Matsuda
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Th2/Th17 reciprocal regulation: twists and turns in the complexity of asthma phenotypes.

Authors:  Jason P Lynch; Manuel A Ferreira; Simon Phipps
Journal:  Ann Transl Med       Date:  2016-10

Review 4.  Early life factors that affect allergy development.

Authors:  Lisa A Reynolds; B Brett Finlay
Journal:  Nat Rev Immunol       Date:  2017-05-15       Impact factor: 53.106

5.  Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.

Authors:  Michelle A Gill; Andrew H Liu; Agustin Calatroni; Rebecca Z Krouse; Baomei Shao; Allison Schiltz; James E Gern; Alkis Togias; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2017-09-01       Impact factor: 10.793

Review 6.  IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies.

Authors:  Chantal Donovan; Philip M Hansbro
Journal:  ACS Pharmacol Transl Sci       Date:  2019-12-20

Review 7.  Type two innate lymphoid cells: the Janus cells in health and disease.

Authors:  Hadi Maazi; Omid Akbari
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

8.  Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.

Authors:  Ann Esquivel; William W Busse; Agustin Calatroni; Alkis G Togias; Kristine G Grindle; Yury A Bochkov; Rebecca S Gruchalla; Meyer Kattan; Carolyn M Kercsmar; G Khurana Hershey; Haejin Kim; Petra Lebeau; Andrew H Liu; Stanley J Szefler; Stephen J Teach; Joseph B West; Jeremy Wildfire; Jaqueline A Pongracic; James E Gern
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

9.  Long-lived regulatory T cells generated during severe bronchiolitis in infancy influence later progression to asthma.

Authors:  Jason P Lynch; Rhiannon B Werder; Bodie F Curren; Md Al Amin Sikder; Ashik Ullah; Ismail Sebina; Ridwan B Rashid; Vivian Zhang; John W Upham; Geoff R Hill; Raymond J Steptoe; Simon Phipps
Journal:  Mucosal Immunol       Date:  2020-02-17       Impact factor: 7.313

10.  Integrated omics endotyping of infants with respiratory syncytial virus bronchiolitis and risk of childhood asthma.

Authors:  Yoshihiko Raita; Marcos Pérez-Losada; Robert J Freishtat; Brennan Harmon; Jonathan M Mansbach; Pedro A Piedra; Zhaozhong Zhu; Carlos A Camargo; Kohei Hasegawa
Journal:  Nat Commun       Date:  2021-06-14       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.